What Did We Learn From IMpower010 in Resectable NSCLC

What Did We Learn From IMpower010 in Resectable NSCLC

At the recent virtual American Society of Clinical Oncology annual meeting, results of the phase III IMpower010 trial demonstrated that adjuvant atezolizumab (Tecentriq) for patients with stage IB to IIIA non-small cell lung cancer (NSCLC) improved disease-free survival in patients with high PD-L1 expression.

In this first of four exclusive episodes, MedPage Today brought together three leaders in the field —  moderator Vinay Prasad, MD, of the University of California San Francisco, is joined by Chul Kim, MD, of Georgetown University and MedStar Health in Washington, D.C., and Andrae Vandross, MD, of NEXT Oncology in San Antonio and Austin — for a roundtable discussion on the goals of adjuvant therapy in the setting of NSCLC, the landscape of treatments, and how the IMpower010 trial might affect their decision-making.

See full article